CagriSema vs Wegovy: Why Wegovy Is the Choice Today
Medically reviewed by Medical Advisory Board Last reviewed 2026-09-22
Wegovy provides immediate FDA approval while CagriSema combines the same semaglutide dose with cagrilintide in ongoing review.
Wegovy is FDA-approved and available in pharmacies today. CagriSema combines cagrilintide with that same 2.4 mg semaglutide dose, but Novo Nordisk submitted the investigational treatment to the FDA in December 2025 and it is not yet approved or available. No head-to-head clinical trial comparing CagriSema against Wegovy or semaglutide has been published. Patients who need medical weight management today have no clinical reason to postpone care while waiting for CagriSema.
Wegovy is the practical option when evaluating CagriSema vs Wegovy because it is FDA-approved and commercially available right now. At The Metabolic Journal, we evaluate clinical trial publications and drug pipeline data to help readers make informed prescription choices. Both therapies come from Novo Nordisk as weekly subcutaneous injections for chronic weight management.
The difference between them centers on approval status and chemical formulation. Wegovy received its initial FDA clearance in June 2021. In contrast, CagriSema is an unapproved investigational candidate. Novo Nordisk submitted CagriSema to the FDA in December 2025, but the drug remains unavailable to patients.
Partner · Opt Health
Want medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →This regulatory gap influences every practical decision. Our reviews of Wegovy vs Zepbound and Ozempic vs Wegovy evaluate medications you can fill at a pharmacy today. In contrast, assessing CagriSema mirrors our review of retatrutide vs tirzepatide by comparing an unapproved pipeline molecule against an approved standard.
CagriSema vs Wegovy at a Glance
CagriSema and Wegovy share the same manufacturer and base molecule, but they differ in regulatory status and chemical composition. Novo Nordisk developed both medications as weekly subcutaneous injections for adult weight management. Wegovy holds active FDA clearance. CagriSema is still under regulatory review.
The table below summarizes how these two therapies compare across clinical and commercial criteria.
| Dimension | CagriSema | Wegovy |
|---|---|---|
| Active ingredients | Cagrilintide 2.4 mg + semaglutide 2.4 mg | Semaglutide 2.4 mg |
| Drug mechanism | Amylin receptor agonist + GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA status | Investigational (submitted December 2025) | FDA-approved (June 2021) |
| Dosing schedule | Once weekly subcutaneous injection | Once weekly subcutaneous injection |
| Headline trial weight loss | 22.7% at 68 weeks (REDEFINE 1) | 14.9% at 68 weeks (STEP-1) |
| Head-to-head status | No trial against semaglutide alone | No trial against CagriSema |
| Cardiovascular data | No completed outcomes trial | 20% MACE reduction (SELECT trial) |
| Estimated list price | Unpublished (not commercially available) | Approximately $1,349 per month |
Wegovy delivers semaglutide alone as a single-agent GLP-1 receptor agonist. CagriSema adds a second compound called cagrilintide to that exact semaglutide dose. This combination creates a dual-action mechanism. Patients cannot fill CagriSema at a retail pharmacy today. Wegovy remains the only accessible option between the two therapies.
The two medications also differ in clinical documentation. Wegovy has completed cardiovascular outcomes research. CagriSema offers promising weight reduction data from recent phase 3 studies. Examining how these trial results compare helps explain why clinicians treat them differently.
What Each Drug Actually Is
Wegovy is a single-agent GLP-1 receptor agonist, whereas CagriSema is a dual-component combination therapy. Novo Nordisk developed both injectables to assist adults with chronic weight management. Each medication uses a once-weekly subcutaneous dosing schedule, but their formulations follow distinct pharmacological designs.
Wegovy contains semaglutide 2.4 mg. The FDA approved Wegovy in June 2021 for chronic weight management in qualifying adults. Semaglutide is a GLP-1 receptor agonist. Patients administer the medication weekly using prefilled pens across standard escalating dosage steps.
CagriSema is an investigational fixed-dose combination therapy. It combines cagrilintide 2.4 mg and semaglutide 2.4 mg into a single injection. Cagrilintide serves as a long-acting amylin receptor agonist. Semaglutide provides the GLP-1 receptor agonist component.
The presence of semaglutide in both drugs is a meaningful distinction for patients. CagriSema contains the exact active ingredient and dose found in Wegovy. Novo Nordisk added cagrilintide to target two distinct hormone pathways in one weekly shot. Novo Nordisk submitted an application to the FDA in December 2025 for chronic weight management based on the REDEFINE 1 and REDEFINE 2 trials.
Is CagriSema the Same Drug as Wegovy
CagriSema is not the same drug as Wegovy because it includes an additional active ingredient that Wegovy does not contain. Many people following metabolic research assume CagriSema is simply a higher dose of Wegovy. That assumption is incorrect. Wegovy contains only semaglutide 2.4 mg.
CagriSema pairs that exact semaglutide dose with cagrilintide 2.4 mg in a single injection. This difference in chemical structure creates two distinct therapies. Wegovy activates GLP-1 receptors alone. CagriSema stimulates both amylin and GLP-1 receptors. Because CagriSema introduces a second active molecule, it requires separate regulatory testing and independent FDA evaluation.
Commercial availability also separates these two treatments. Wegovy is stocked in retail pharmacies nationwide. CagriSema cannot be purchased anywhere today. It remains an investigational candidate undergoing formal federal evaluation.
The FDA has not issued an official approval decision date for CagriSema. Novo Nordisk submitted its regulatory application in December 2025, but evaluation timelines can vary widely. Patients should not plan immediate medical care around speculative approval estimates.
Weight Loss Results in Clinical Trials for CagriSema vs Wegovy
Clinical trials showed higher percentage weight loss for CagriSema than for Wegovy, but the two drugs have never competed in a direct head-to-head trial. Each medication was studied in separate clinical research programs with different participant groups. Comparing headline numbers provides helpful context. However, cross-trial comparisons do not provide scientific proof of superiority.
Novo Nordisk evaluated Wegovy in the STEP-1 clinical trial. In that 68-week study, participants taking semaglutide 2.4 mg achieved an average weight loss of approximately 14.9%. Roughly 32% of participants in STEP-1 lost 20% or more of their baseline body weight. These outcomes confirmed semaglutide as an effective prescription option for chronic weight management.
CagriSema was evaluated in the REDEFINE 1 trial, published in the New England Journal of Medicine on June 22, 2025. This 68-week, phase 3 trial enrolled 3,417 adults with obesity or overweight plus at least one weight-related condition, without diabetes. Under the efficacy estimand representing full treatment adherence, CagriSema 2.4 mg/2.4 mg produced a mean 22.7% weight reduction. Placebo participants lost 2.3% of their body weight. Furthermore, 97.6% of CagriSema patients achieved at least 5% weight loss under that same estimand.
These trial numbers cannot be compared directly. STEP-1 and REDEFINE 1 evaluated different populations under separate trial protocols. No published study has tested CagriSema directly against semaglutide alone. The only confirmed head-to-head trial for CagriSema evaluated it against tirzepatide in REDEFINE 4, which we cover in our analysis of CagriSema vs Zepbound. Until researchers test CagriSema directly against Wegovy, verified claims of clinical superiority remain unavailable.
Cardiovascular Evidence and Safety Profiles
Wegovy provides proven cardiovascular risk reduction, whereas CagriSema has only established safety and tolerability in early clinical trials. This difference in cardiovascular evidence is an important clinical distinction. Prescribers evaluate total health outcomes alongside weight loss.
In the 2023 SELECT cardiovascular outcomes trial, Wegovy demonstrated a statistically significant 20% reduction in major adverse cardiovascular events (MACE). The study enrolled adults with established cardiovascular disease and overweight or obesity. This trial established that Wegovy offers heart health benefits in addition to weight reduction.
CagriSema does not currently possess equivalent cardiovascular outcome data. Novo Nordisk reported CagriSema's safety profile as safe and well-tolerated across its phase 3 program. Gastrointestinal adverse events occurred most frequently. These digestive symptoms match the known side effects of GLP-1 receptor agonists, including Wegovy.
Reported side effects were mostly mild-to-moderate and diminished over time. Nausea faded quickly. Adding cagrilintide did not introduce unexpected safety categories in published trial reports. However, CagriSema still lacks the completed long-term cardiovascular evidence that Wegovy holds today.
Cost and Availability of CagriSema vs Wegovy
Wegovy carries an established list price of approximately $1,349 per month, while CagriSema has no commercial price because it remains unapproved. This financial difference directly affects patient access. Wegovy is a commercially available prescription medication distributed through licensed retail and specialty pharmacies.
The list price of roughly $1,349 per month applies before insurance coverage or manufacturer savings programs. Actual out-of-pocket costs vary based on individual insurance plans and pharmacy benefit designs. Patients with qualifying coverage can often access commercial savings cards to reduce their monthly payments.
CagriSema has no approved retail price in the United States. Pharmacies cannot stock or dispense the experimental medication. Novo Nordisk cannot establish pricing or copay programs until the FDA grants regulatory clearance. Speculation about future insurance coverage remains unverified at this stage.
This availability gap clarifies who should consider each treatment. Patients needing active weight management cannot use an unapproved drug. Delaying care offers no clinical benefit when Wegovy is available and delivers the same semaglutide dose. Wegovy provides immediate treatment access. CagriSema remains a pipeline candidate for the future.
The Verdict
Wegovy is our practical recommendation for medical weight loss today because it is FDA-approved, widely available, and delivers the exact semaglutide dose found in CagriSema. Novo Nordisk demonstrated 22.7% weight loss with CagriSema in the REDEFINE 1 trial. However, that study did not test the combination directly against semaglutide alone. Wegovy also provides proven cardiovascular risk reduction that CagriSema has not yet established.
This waiting strategy is not for anyone who needs active medical therapy for obesity today. Postponing care offers no clinical advantage when an approved medication is already available. Waiting on CagriSema only makes sense for patients who have discussed clinical timelines with their doctor and choose to follow experimental amylin research.
Our recommendation would change under specific conditions. FDA approval of CagriSema, a published trial proving superiority over semaglutide alone, or competitive commercial pricing would prompt us to re-evaluate both options. Until those events occur, Wegovy holds both the commercial availability advantage and the documented cardiovascular record.
Consult a licensed healthcare provider today. They can determine whether Wegovy fits your health profile. If you are comparing cagrisema vs wegovy, take our free assessment to evaluate your metabolic markers and prepare for your provider visit.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.
Frequently Asked Questions
Is CagriSema the same as Wegovy?
No, CagriSema is not the same as Wegovy. CagriSema is a fixed-dose combination therapy that pairs cagrilintide 2.4 mg, an amylin receptor agonist, with semaglutide 2.4 mg, a GLP-1 receptor agonist. Wegovy contains only semaglutide 2.4 mg. While both medications contain the exact same semaglutide dose, CagriSema adds a second active ingredient and remains an unapproved investigational drug.
When will CagriSema be available?
CagriSema is not commercially available, and no official approval date exists. Novo Nordisk submitted CagriSema to the FDA in December 2025 for a chronic weight management indication. The FDA is currently reviewing the application, but regulatory evaluations take time and can involve requests for additional data. Until the FDA completes its review and grants approval, CagriSema cannot be prescribed or dispensed in the United States.
Does CagriSema work better than Wegovy for weight loss?
Clinical trial evidence cannot verify whether CagriSema works better than Wegovy because no published head-to-head trial has compared them directly. In separate studies, CagriSema achieved a 22.7% mean weight reduction in the REDEFINE 1 trial, while Wegovy achieved a 14.9% average weight reduction in the STEP-1 trial. However, differing study protocols, baseline criteria, and participant populations prevent direct comparison between these two trial results.
How much does CagriSema cost?
CagriSema has no approved price in the United States. Because the medication is still an unapproved investigational candidate, Novo Nordisk has not released commercial list pricing, wholesale acquisition costs, or patient assistance terms. By comparison, Wegovy has an established list price of approximately $1,349 per month before insurance coverage or manufacturer savings programs.
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Want weight loss handled by a physician who works from your labs? See how Opt Health does it →
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Comparisons
-
Ozempic vs Wegovy: Same Drug (Semaglutide), Different Use and Dose
Ozempic vs Wegovy: both are semaglutide — the real differences in approval, dose, and coverage.
-
Saxenda vs Wegovy: Daily Liraglutide vs Weekly Semaglutide Weight-loss Injection Compared
Saxenda vs Wegovy: daily liraglutide vs weekly semaglutide — trial results, convenience, and track record.
-
Foundayo vs Wegovy: Daily GLP-1 Pill vs Weekly GLP-1 Injection Compared
Foundayo vs Wegovy: daily GLP-1 pill vs weekly GLP-1 injection — same mechanism, different delivery.
See more related comparisons
-
Wegovy vs Zepbound: Same Mechanism, Different Numbers — Which FDA-approved Weight-loss Injection Wins?
Wegovy vs Zepbound: FDA-approved weight-loss injections compared on results, CV data, and cost.
-
Wegovy vs Mounjaro: On-label Weight-loss Approval vs Off-label Diabetes Drug Compared
Wegovy vs Mounjaro: on-label weight-loss approval vs off-label diabetes drug compared.
-
CagriSema vs Zepbound: Novo Nordisk's REDEFINE 4 Head-to-head Trial Results, FDA Status, and Which Is Available Today
CagriSema vs Zepbound: Novo Nordisk's REDEFINE 4 head-to-head trial, FDA approval status, and which is actually available today.
-
CagriSema vs Ozempic: How the Investigational Combo Differs From Approved Semaglutide, and Which Is Available Today
CagriSema vs Ozempic: how the investigational combo differs from approved semaglutide, and which is available today.
-
Wegovy Alternatives: 6 Options Compared for Weight Management
Wegovy alternatives ranked: Zepbound, off-label Ozempic, compounded semaglutide, metformin, lifestyle.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.